Remove 2030 Remove Licensing Remove Regulations
article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

billion) Healthcare Innovation 2030 project, with ambitious plans to turn France into the European leader in health innovation by 2030. Since the launch of Healthcare Innovation 2030, investment has continued apace in the region. billion ($7.9

Drugs 147
article thumbnail

Conversations from Cancer Research Horizons’ Innovation Summit 2023 

Drug Discovery World

He said: “Between now and 2030, we’re going to see a range of vaccines using various technologies. As for Infinitopes, the company’s trials will begin in 2024. Covid, she says, proved to us what could be done in a very short period of time, particularly in the case of the mRNA vaccine. He said: “We welcome the announcement today.

Research 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article EMA Thank You U.K. regulator lays out proposal for international device and diagnostics recognition

Agency IQ

regulator lays out proposal for international device and diagnostics recognition The British medical device regulator just issued its promised framework on international recognition. law as the Medical Devices Regulation 2002 (UK MDR 2002). law as the Medical Devices Regulation 2002 (UK MDR 2002).

article thumbnail

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

The Pharma Data

Pipeline progress is expected across the vaccines, therapeutics, and devices portfolios, anticipating at least one Phase 3 launch and one Biologics License Application (BLA)/Emergency Use Authorization (EUA) filing. In working together, we envision protecting or enhancing 1 billion lives by 2030. FOOTNOTES. (1)

article thumbnail

A Final LDT Rule in April!? Will FDA be prepared?

FDA Law Blog: Biosimilars

1] Yet FDA’s conclusions about the Agency’s ability to regulate the entire laboratory industry are based on fundamentally flawed assumptions about the number of entities and tests that will be subject to FDA regulation. 5] This stratification, though, assumes that LDTs will follow the same pattern as IVDs currently regulated by FDA.

FDA 69
article thumbnail

Analysis Chemical Thank You Highlights of the EPA’s Unified Agenda for Spring 2023

Agency IQ

Highlights of the EPA’s Unified Agenda for Spring 2023 The Office of Management and Budget has released the Unified Agenda for Spring 2023, which outlines the regulations that agencies expect to release in 2023 and 2024. This information would be used in considering the regulation of asbestos.